Figure 2

Exploratory efficacy end-points before and after endobronchial infusion of adipose derived stromal cells-stromal vascular fraction (ADSCs-SVF). A. Forced vital capacity (FVC)% pred. over time for each subject. Each line represents measurements made in a single subject. A time point 0 months indicates when first endobronchial infusion of the ADSCs-SVF was performed. As depicted, there were no statistically significant alterations between baseline and after 6 and 12 months following 1^st endobronchial infusion. A time point −3 months indicates period of time prior treatment initiation. B . Diffusion lung capacity for carbon monoxide (DL_CO)% pred. over time for each subject. Each line represents measurements made in a single subject. As depicted, there were no statistically significant alterations between baseline and after 6 and 12 months following 1^st endobronchial infusion. A time point 0 months indicates when first endobronchial infusion of ADSCs-SVF was performed. A time point −3 months indicates period of time prior treatment initiation. C . 6-minute walking distance (6MWD) over time. As depicted, there were no statistically significant alterations between baseline and after 6 and 12 months following 1^st endobronchial infusion of the ADSCs-SVF. A time point −3 months indicates period of time prior treatment initiation. D . Saint George’s Research Questionnaire (SGRQ) score over time. A time point 0 months indicates when first endobronchial infusion of the ADSCs-SVF was performed. As depicted, there was a statistically significant decline between baseline (0 months) and after 6 and 12 months following 1^st endobronchial infusion. *p<0.05.